Skip to main content

10-05-2021 | EASD 2021 | Conference coverage | News

News in brief

Semaglutide treatment may reduce systemic inflammation

Eleanor McDermid

medwireNews: Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein (hsCRP), indicates further analysis of the PIONEER and SUSTAIN trials.

Ofri Mosenzon (Hadassah Medical Center, Jerusalem, Israel) presented the data from the PIONEER 1, 2, and 5 trials plus SUSTAIN 3 – those that had hsCRP values available.

These data revealed that treatment with oral or injectable semaglutide resulted in a significant reduction in average hsCRP levels from baseline and versus most comparator treatments – placebo, exenatide, and empagliflozin.

The effect of semaglutide on hsCRP was partly mediated through its impact on glycated hemoglobin (accounting for 22.6 to 38.9% of the effect) and on bodyweight (5.3 to 50.3%), with the two together explaining 21.4% to 61.6%. However, the analysis also indicated that semaglutide had a direct effect on hsCRP levels.

Addressing delegates at the virtual 57th EASD Annual Meeting, Mosenzon noted that reduction of systemic inflammation may be one pathway through which glucagon-like peptide-1 receptor agonists reduce cardiovascular risk in people with type 2 diabetes.

She said that further insights should come from the ongoing SOUL and SELECT trials, which are assessing the cardioprotective ability of oral semaglutide and weekly injectable semaglutide 2.4 mg, respectively.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

EASD Annual Meeting; Sept 27–Oct 1, 2021

EASD Annual Meeting 2021 coverage

Access all of our ongoing coverage including the latest news and expert video interviews.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.